Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00454337 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load

Study acronym: EASIER
StatusCompleted
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv10
  2. Publications: 3 to 9v9 Show moreShow less

    See this version in full on ClinicalTrials.gov ↗

  3. Interventions: Enfuvirtide (Drug), Raltegravir (Drug) to FTC/TDF + EFV or LPV/R (Drug), FTC/TDF + EFV or LPV/R +T20 (Drug) Secondary endpoints revised (10) · Study arms: 0 to 2v8 Show all 3 changesShow less
    • Secondary endpoints revised (10)
    • Study arms: 0 to 2

    See this version in full on ClinicalTrials.gov ↗

  4. Trial status: Active, Not Recruiting to Completed Start date: Apr 2007 to May 2007v7 Show all 2 changesShow less
    • Start date: Apr 2007 to May 2007
  5. Primary and study completion dates: Sep 2008v6
Show 4 earlier versionsHide 4 earlier versions
  1. Re-verified, no change to tracked fieldsv5
  2. Trial status: Recruiting to Active, Not Recruiting Site details revisedv4 Show all 2 changesShow less
    • Site details revised
  3. Trial status: Not Yet Recruiting to Recruiting Site details revisedv3 Show all 2 changesShow less
    • Site details revised
  4. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Switching from enfuvirtide to raltegravir in the treatment of HIV-infected patients who sustain viral suppression with a combination therapy including enfuvirtide (or : with an enfuvirtide-based combination therapy)
Trial Details
NCT Number NCT00454337
Lead Sponsor French National Agency for Research on AIDS and Viral Hepatitis
Collaborators: Merck Sharp & Dohme LLC
Conditions HIV Infections
Enrollment 170 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov